Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.

  title={Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.},
  author={Diana Gkeok-Stzuan Lim and Joanne Ngeow},
  journal={Endocrine-related cancer},
  volume={23 6},
The effectiveness of poly (ADP-ribose) polymerase inhibitors (PARPi) in treating cancers associated with BRCA1/2 mutations hinges upon the concept of synthetic lethality and exemplifies the principles of precision medicine. Currently, most clinical trials are recruiting patients based on pathological subtypes or have included BRCA mutation analysis (germ line and/or somatic) as part of the selection criteria. Mounting evidence, however, suggests that these drugs may also be efficacious in… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 12 extracted citations

BRCA1/2 testing: therapeutic implications for breast cancer management

British Journal of Cancer • 2018
View 3 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 139 references

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2014
View 4 Excerpts
Highly Influenced

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

Proceedings of the National Academy of Sciences of the United States of America • 2013
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…